Jeffrey Lipman

Prof Lipman is Executive Director of the Burns Trauma & Critical Care Research Centre; Professor of Anesthesiology & Critical Care, The University of Queensland and until recently (for 23 years) was Director of Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital; He holds Honorary Professorial appointments at Chinese University of Hong Kong, Unversity of Witwatersrand (South Africa) and Qeensland University of Technology.

He has qualifications in anesthesia and intensive care and has set up and been in charge of a number of Intensive Care and Trauma Units in South Africa before coming to Australia in 1997. he currently manages a large multidisciplinary research team with an output of over 120 peer-reviewed articles per annum. He has supervised dozens of PhD students to completion and is currently supervising 6 PhD, 1 MPhil and 1 MBBS/Hons students. Prof Lipman has been instrumental in developing the anaesthesiology and critical care component of a graduate medical program for Queensland and continues to lecture to medical and postgraduate students.

Prof Lipman is the author of over 550 peer reviewed publications, 30 book chapters and has been invited to deliver over 120 lectures at national and international conferences in many countries across the world. His research interests include all aspects of infection management in intensive care and he has a special interest in the pharmacokinetics of antibiotic dosage, an area in which he received his MD in 2006. His research into antibiotic usage in acute situations has received international recognition and he is regarded as an expert in the field. As such, he and his research team have conducted and presently conduct a number of clinical trials in Australia, New Zealand, Hong Kong, Europe and the UK.

Prof Lipman is an Editorial Board member for 10 International Journals, is Section Editor on four Antibiotic related Journals, reviews for 23 journals and is an external reviewer for NHMRC project grants (Local) as well as equivalent for a number overseas countries.

He is Chief Investigator on a 7000 patient International Randomised Controlled Trial comparing bolus dosing versus continuous infusions of meropenem and piperacillin-tazobactam